Moderna inks deal with Takeda for 50M doses of COVID-19 vaccine in Japan

• Takeda Pharmaceutical (NYSE:TAK) will import and distribute 50M doses of Moderna’s (NASDAQ:MRNA) COVID-19 vaccine candidate, mRNA-1273, starting in H1 2021, pending licensure in Japan.
• This effort is part of a three-way agreement among Takeda, Moderna and the Government of Japan’s Ministry of Health Labour and Welfare (MHLW).
• Under the terms of the new agreement, Takeda will be responsible for securing the necessary regulatory approvals prior to distributing Moderna’s COVID-19 vaccine candidate in Japan. Moderna will provide finished product and will support Takeda with its development and regulatory efforts.
• Moderna's 30,000 participant Phase 3 trial of mRNA-1273 at the 100 µg dose level in the U.S. is fully enrolled.
• https://seekingalpha.com/news/3627928-moderna-inks-deal-takeda-for-50m-doses-of-covidminus-19-vaccine-in-japan